Chongqing Taiji Industry (Group) Co., Ltd. Class A

Chongqing Taiji Industry (Group) Co., Ltd. Class A

SSSE:600129
12.11
CNY
-0.10
(-0.82%)
-0.05EPS
7.47BMarket Cap
Mar 26Next Earn
Chongqing Taiji Industry (Group) Co., Ltd. Class A
SSE:600129
(Shanghai Stock Exchange)

Recent

price

12.11

P/E

ratio

- -

div

yld

2.24%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
14.02
15.44
15.57
15.77
16.3
16.72
18.67
20.65
19.78
21.37
20.36
21.83
25.51
28.12
23.24
19.16
17.42
Revenue per Share
-0.4
0.05
-0.52
0.03
-0.65
0.54
2.01
0.23
0.13
-0.13
0.12
-0.94
0.64
1.48
0.05
0.22
-0.04
Basic EPS, GAAP
-0.75
-0.53
-0.41
-1.21
-1.24
-0.93
-1.02
-1.44
-1.09
-1.21
-0.09
0.11
2.26
-0.3
-2.74
0.11
- -
Free Cash Flow per Basic Share
0.32
0.51
0.52
0.58
0.59
0.64
0.51
0.84
0.43
0.56
0.47
0.32
0.28
0.24
0.56
0.22
0.27
Dividend per Share
2.53
2.62
2.11
2.22
2.37
2.37
2.99
2.89
5.92
5.7
5.81
4.9
5.55
6.5
6.27
6.35
6.41
Book Value per Share
-1.53
-1.48
-2.43
-1.07
-0.9
-0.37
0.27
0.01
3.63
3.1
3.35
2.44
3.19
3.87
3.5
3.68
3.79
Tangible Book Value per Share
427
414
424
419
427
429
426
425
540
545
551
557
554
555
533
548
550
Basic Weighted Avg Shares
5,986
6,386
6,603
6,603
6,958
7,171
7,952
8,773
10,689
11,643
11,208
12,149
14,127
15,623
12,386
10,500
9,588
Sales/Revenue/Turnover
2.25
2.49
1.56
2.7
1.52
-2.69
-3.63
4.74
4.98
2.62
-0.34
-0.37
5.67
8.47
4.91
4.14
2.9
Operating Margin (%)
152
146
151
156
161
169
195
204
216
246
276
381
424
438
431
471
- -
Depreciation Expense
-172
21
-220
13
-277
232
856
98
70
-71
66
-523
354
822
27
121
-20
Net Income, GAAP
- -
46.77
- -
30.88
- -
37.63
2.96
48.01
55.74
247.82
78.99
- -
23.22
16.86
84.16
45.44
142.03
Effective Tax Rate (%)
-2.88
0.32
-3.34
0.19
-3.98
3.23
10.77
1.11
0.66
-0.61
0.59
-4.31
2.51
5.26
0.22
1.15
-0.2
Profit Margin (%)
-1,248
-1,361
-1,740
-834
-1,922
-2,326
-1,855
-2,468
-148
-1,568
-1,070
-2,291
-2,254
-1,944
-2,651
-2,676
-2,668
Working Capital
664
426
967
1,333
302
98
869
871
1,361
817
1,663
823
620
444
419
465
430
LT Debt
1,579
1,622
1,492
1,499
1,599
1,303
1,270
1,228
3,285
3,136
3,165
2,602
2,957
3,746
3,633
3,642
3,660
Total Equity
- -
-1.05
- -
-1.75
- -
3.87
16.26
1.61
0.91
-1.48
0.4
- -
4.46
10.82
0.74
1.46
-0.36
Return on Invested Capital (%)
- -
2.95
- -
4.02
- -
8.84
21.04
3.68
2.58
-4.52
1.81
- -
6.45
11.67
0.28
2.2
-0.74
Return on Capital (%)
-14.69
1.88
-21.82
1.36
-28.21
22.86
74.76
7.78
3.1
-2.19
2.06
-17.55
12.19
24.5
0.75
3.45
-0.55
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
5,065
5,088
5,004
LT Borrowings
375
331
338
LT Finance Leases
103
100
92
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
551
551
551
Market Capitalization
9,198
7,483
7,466

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
7,422
7,134
6,744
Cash, Cash Equivalents & STI
732
740
518
Accounts Receivable, Net
3,030
2,941
2,809
Inventories
2,250
2,243
2,118
Total Current Liabilities
10,052
9,754
9,412
Payables & Accruals
- -
- -
- -
ST Debt
5,065
5,088
5,004
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.78%
3.95%
0.23%
Free Cash Flow
235.46%
477.76%
-104.15%
Net Income, GAAP
-91.31%
-134.4%
352.38%
Sales/Revenue/Turnover
4.75%
-0.14%
-15.23%
Total Cash Common Dividend
2.83%
1.08%
-59.11%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,208
3,609
2,617
1,952
12,386
2025
2,828
2,830
- -
2,412
10,500
2026
2,528
2,556
2,092
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.44
0.09
-0.93
0.05
2025
0.13
0.12
- -
-0.08
0.22
2026
0.12
0.04
-0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.36
0.05
0.07
0.56
2025
0.05
0.06
- -
0.07
0.22
2026
0.05
0.05
0.1
- -
- -
Business
Chongqing Taiji Industry (Group) Co., Ltd. (600129.SS) develops, manufactures, and sells traditional Chinese medicines and modern pharmaceuticals in China and select international markets. The company operates through Pharmaceutical Industry, Pharmaceutical Commercial, Chinese Herbal Medicine Resources, Big Health, and Service Industry and Others segments; it offers digestive system and metabolic drugs such as trimetazidine and Bushenyishou capsules, respiratory system drugs including acute bronchitis syrup and Huoxiangzhengqi oral liquid, cardiovascular and cerebrovascular drugs like Tongtian oral liquid and Salvia oral solution, anti-infective drugs, nervous system drugs, anti-tumor and immunomodulatory drugs such as paclitaxel and Xiaojin tablets, health products, and chemical medicines including Taiji Ginseng Extract and Taiji Bile Powder; it also engages in pharmaceutical distribution and retail, medicinal material planting research and development, accommodation, warehousing, catering, retail, agriculture, wholesale, and aquaculture activities. Founded in 1972 and headquartered at No. 18 Hengshan East Road, Yubei District, Chongqing, China, the company maintains over 10 manufacturing facilities across China adhering to GMP standards, employs approximately 11,971 people, and generates the majority of its revenue from Southwest China with additional sales in East, Northern, South, Central, North-West, and North-East China as well as overseas markets. In late 2024, Chongqing Taiji Industry announces plans to acquire 100% equity in Taiji Group Chongqing Tongjun Pavilion Pharmaceutical Factory for 147.3 million yuan with a 320 million yuan capital increase and full equity in Taiji Group Chongqing Traditional Chinese Medicine Factory No. 2 for 29.8 million yuan with a 185 million yuan capital increase to expand its production capabilities; the board authorizes a share buyback plan in July 2025, and the company reports earnings for Q1 2025 and full-year 2024 while maintaining strategic financial services agreements with Sinopharm Group Finance Co., Ltd.